Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group

Paula CramerDepartment I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, University of Cologne, Cologne, GermanyCorrespondence[email protected]

Anna-Maria FinkDepartment I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, University of Cologne, Cologne, Germany

Raymonde BuschTechnical University, Institute for Medical Statistics and Epidemiology, Munich, Germany

Barbara EichhorstDepartment I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, University of Cologne, Cologne, Germany

Clemens-Martin WendtnerDepartment of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, Klinikum Schwabing, Munich, Germany

Natali PflugDepartment I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, University of Cologne, Cologne, Germany

Petra LangerbeinsDepartment I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, University of Cologne, Cologne, Germany

Jasmin BahloDepartment I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, University of Cologne, Cologne, Germany

Valentin GoedeDepartment I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, University of Cologne, Cologne, Germany

Friederike SchubertDepartment I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, University of Cologne, Cologne, Germany

Hartmut DöhnerDepartment III of Internal Medicine, University Hospital Ulm, Ulm, Germany

Stephan StilgenbauerDepartment III of Internal Medicine, University Hospital Ulm, Ulm, Germany

Peter DregerDepartment V of Medicine, University of Heidelberg, Heidelberg, Germany

Michael KnebaDepartment II of Internal Medicine, University Hospital Schleswig-Holstein, Kiel, Germany

Sebastian BöttcherDepartment II of Internal Medicine, University Hospital Schleswig-Holstein, Kiel, Germany

Jiri MayerDepartment of Hemato-Oncology, University Hospital Brno, Brno, Czech Republic

Michael HallekDepartment I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, University of Cologne, Cologne, Germany

Kirsten FischerDepartment I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, University of Cologne, Cologne, Germany

show all

References

Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164–1174.
PubMed Web of Science ®Google Scholar
Robak T, Dmoszynska A, Solal-Celigny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010;28: 1756–1765.
PubMed Web of Science ®Google Scholar
Eichhorst B, Dreyling M, Robak T, et al. Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011;22(Suppl. 6):vi50–vi54.
PubMed Web of Science ®Google Scholar
Fink A, Pflug N, Busch R, et al. Serum factors predict therapeutic outcome in patients with chronic lymphocytic leukemia treated in the CLL8 trial of the German CLL Study Group (GCLLSG). Blood 2010;116(Suppl. 1): Abstract 918.
Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date